AU2009264336A1 - Methods for preparing human skin substitutes from human pluripotent stem cells - Google Patents
Methods for preparing human skin substitutes from human pluripotent stem cells Download PDFInfo
- Publication number
- AU2009264336A1 AU2009264336A1 AU2009264336A AU2009264336A AU2009264336A1 AU 2009264336 A1 AU2009264336 A1 AU 2009264336A1 AU 2009264336 A AU2009264336 A AU 2009264336A AU 2009264336 A AU2009264336 A AU 2009264336A AU 2009264336 A1 AU2009264336 A1 AU 2009264336A1
- Authority
- AU
- Australia
- Prior art keywords
- human
- cells
- stem cells
- pluripotent stem
- keratinocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 57
- 210000001778 pluripotent stem cell Anatomy 0.000 title claims description 54
- 210000004027 cell Anatomy 0.000 claims description 177
- 210000002510 keratinocyte Anatomy 0.000 claims description 137
- 210000003491 skin Anatomy 0.000 claims description 86
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 40
- 230000004069 differentiation Effects 0.000 claims description 38
- 210000002950 fibroblast Anatomy 0.000 claims description 38
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 30
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 24
- 230000007170 pathology Effects 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 21
- 210000004207 dermis Anatomy 0.000 claims description 21
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 19
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 18
- 235000010323 ascorbic acid Nutrition 0.000 claims description 17
- 239000011668 ascorbic acid Substances 0.000 claims description 17
- 229960005070 ascorbic acid Drugs 0.000 claims description 17
- 239000001963 growth medium Substances 0.000 claims description 17
- 230000006698 induction Effects 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 238000004113 cell culture Methods 0.000 claims description 13
- 230000037380 skin damage Effects 0.000 claims description 13
- 238000012258 culturing Methods 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 230000011712 cell development Effects 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000012598 cell culture matrix Substances 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 2
- 210000002615 epidermis Anatomy 0.000 description 34
- 239000010410 layer Substances 0.000 description 32
- 230000014509 gene expression Effects 0.000 description 30
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 26
- 238000010171 animal model Methods 0.000 description 24
- 238000000338 in vitro Methods 0.000 description 23
- 239000002609 medium Substances 0.000 description 22
- 102100025756 Keratin, type II cytoskeletal 5 Human genes 0.000 description 20
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 18
- 238000001727 in vivo Methods 0.000 description 17
- 208000027418 Wounds and injury Diseases 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 210000000130 stem cell Anatomy 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 108010070553 Keratin-5 Proteins 0.000 description 13
- 108010066321 Keratin-14 Proteins 0.000 description 12
- 238000003753 real-time PCR Methods 0.000 description 12
- 229960004857 mitomycin Drugs 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 206010052428 Wound Diseases 0.000 description 10
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 238000012512 characterization method Methods 0.000 description 8
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 101000614436 Homo sapiens Keratin, type I cytoskeletal 14 Proteins 0.000 description 7
- 101001056473 Homo sapiens Keratin, type II cytoskeletal 5 Proteins 0.000 description 7
- 101710183391 Keratin, type I cytoskeletal 14 Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 108010028309 kalinin Proteins 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 6
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 6
- 108010066327 Keratin-18 Proteins 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 102000006495 integrins Human genes 0.000 description 6
- 108010044426 integrins Proteins 0.000 description 6
- 210000001082 somatic cell Anatomy 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 101000998020 Homo sapiens Keratin, type I cytoskeletal 18 Proteins 0.000 description 5
- 101000975496 Homo sapiens Keratin, type II cytoskeletal 8 Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000000975 bioactive effect Effects 0.000 description 5
- 238000009795 derivation Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000012679 serum free medium Substances 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- 208000026350 Inborn Genetic disease Diseases 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 108010070511 Keratin-8 Proteins 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 208000016361 genetic disease Diseases 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 229930002330 retinoic acid Natural products 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000009016 Cholera Toxin Human genes 0.000 description 3
- 108010049048 Cholera Toxin Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 3
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 3
- 108010065038 Keratin-10 Proteins 0.000 description 3
- 229930192392 Mitomycin Natural products 0.000 description 3
- 229940088623 biologically active substance Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 102000007236 involucrin Human genes 0.000 description 3
- 108010033564 involucrin Proteins 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 2
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 2
- 101001015006 Homo sapiens Integrin beta-4 Proteins 0.000 description 2
- 101000976051 Homo sapiens Involucrin Proteins 0.000 description 2
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 2
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 description 2
- 102100032816 Integrin alpha-6 Human genes 0.000 description 2
- 102100033000 Integrin beta-4 Human genes 0.000 description 2
- 102100023967 Keratin, type I cytoskeletal 12 Human genes 0.000 description 2
- 102100022905 Keratin, type II cytoskeletal 1 Human genes 0.000 description 2
- 102100025759 Keratin, type II cytoskeletal 3 Human genes 0.000 description 2
- 108010070514 Keratin-1 Proteins 0.000 description 2
- 108010065086 Keratin-12 Proteins 0.000 description 2
- 108010066302 Keratin-19 Proteins 0.000 description 2
- 108010070918 Keratin-3 Proteins 0.000 description 2
- 208000034607 Kindler epidermolysis bullosa Diseases 0.000 description 2
- 201000004290 Kindler syndrome Diseases 0.000 description 2
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 238000001190 Q-PCR Methods 0.000 description 2
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 2
- 101150086694 SLC22A3 gene Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003021 clonogenic effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 208000002169 ectodermal dysplasia Diseases 0.000 description 2
- 208000031068 ectodermal dysplasia syndrome Diseases 0.000 description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
- 210000002514 epidermal stem cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000010185 immunofluorescence analysis Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 108010075526 keratohyalin Proteins 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 210000000498 stratum granulosum Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000002993 trophoblast Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102100021238 Dynamin-2 Human genes 0.000 description 1
- 208000010975 Dystrophic epidermolysis bullosa Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 102000000426 Integrin alpha6 Human genes 0.000 description 1
- 108010022238 Integrin beta4 Proteins 0.000 description 1
- 102000012334 Integrin beta4 Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100024629 Laminin subunit beta-3 Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 101710167839 Morphogenetic protein Proteins 0.000 description 1
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 1
- 101710143113 Mothers against decapentaplegic homolog 5 Proteins 0.000 description 1
- 102100030610 Mothers against decapentaplegic homolog 5 Human genes 0.000 description 1
- 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 102000005601 Receptor-Regulated Smad Proteins Human genes 0.000 description 1
- 108010084447 Receptor-Regulated Smad Proteins Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 101700032040 SMAD1 Proteins 0.000 description 1
- 101700026522 SMAD7 Proteins 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102100036790 Tubulin beta-3 chain Human genes 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 101150067309 bmp4 gene Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006003 cornification Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000024690 epidermis development Effects 0.000 description 1
- 208000004298 epidermolysis bullosa dystrophica Diseases 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- -1 fatty acid esters Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000012755 real-time RT-PCR analysis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013376 serial cultivation Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 231100000108 skin corrosion Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0629—Keratinocytes; Whole skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/10—Hair or skin implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides or bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/395—Thyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08305320 | 2008-06-25 | ||
| EP08305320.7 | 2008-06-25 | ||
| EP08305447 | 2008-08-04 | ||
| EP08305447.8 | 2008-08-04 | ||
| US9095708P | 2008-08-22 | 2008-08-22 | |
| US61/090,957 | 2008-08-22 | ||
| EP09305077.1 | 2009-01-28 | ||
| EP09305077 | 2009-01-28 | ||
| PCT/EP2009/057817 WO2009156398A1 (en) | 2008-06-25 | 2009-06-23 | Methods for preparing human skin substitutes from human pluripotent stem cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2009264336A1 true AU2009264336A1 (en) | 2009-12-30 |
Family
ID=40863382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009264336A Abandoned AU2009264336A1 (en) | 2008-06-25 | 2009-06-23 | Methods for preparing human skin substitutes from human pluripotent stem cells |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110165130A1 (enExample) |
| EP (1) | EP2297299A1 (enExample) |
| JP (1) | JP2011525370A (enExample) |
| KR (1) | KR20110022713A (enExample) |
| CN (1) | CN102186969A (enExample) |
| AU (1) | AU2009264336A1 (enExample) |
| BR (1) | BRPI0914422A2 (enExample) |
| WO (1) | WO2009156398A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010134619A1 (ja) * | 2009-05-18 | 2010-11-25 | 国立大学法人東北大学 | 人工多能性幹細胞からの上皮系前駆細胞・幹細胞群及び角膜上皮細胞群の分化誘導方法 |
| US8529883B2 (en) | 2010-05-07 | 2013-09-10 | Fibrocell Technologies, Inc. | Dosage unit formulations of autologous dermal fibroblasts |
| RU2458983C1 (ru) * | 2011-07-18 | 2012-08-20 | Российская Федерация, От Имени Которой Выступает Министерство Образования И Науки Российской Федерации | Способ получения индуцированных плюрипотентных стволовых клеток из фибробластов пациентов с болезнью хангингтона |
| US20160237400A1 (en) * | 2013-03-15 | 2016-08-18 | The Jackson Laboratory | Isolation of non-embryonic stem cells and uses thereof |
| EP2970892A1 (en) * | 2013-03-15 | 2016-01-20 | The Jackson Laboratory | Isolation of non-embryonic stem cells and uses thereof |
| US9545302B2 (en) | 2013-11-20 | 2017-01-17 | Dermagenesis Llc | Skin printing and auto-grafting |
| CN104789521B (zh) * | 2014-01-22 | 2017-11-07 | 广州康睿生物医药科技股份有限公司 | 一种晶状体上皮干细胞的分离培养方法 |
| KR102354410B1 (ko) * | 2014-02-21 | 2022-01-21 | 다이니뽄 스미토모 세이야쿠 가부시키가이샤 | 눈 질환 치료제, 이의 스크리닝 방법, 및 망막 색소 상피 세포 이식과 연관된 거부 반응의 예측 방법 |
| US20180230436A1 (en) * | 2014-10-10 | 2018-08-16 | Garrett VYGANTAS | Methods of manufacturing keratin products and uses thereof |
| US10167451B2 (en) | 2014-12-22 | 2019-01-01 | The Chinese University Of Hong Kong | Combinational use of mechanical manipulation and programin derivatives to increase Oct4, Sox2, or Nanog expression in fibroblasts |
| JP6736253B2 (ja) * | 2014-12-22 | 2020-08-05 | ザ チャイニーズ ユニバーシティ オブ ホンコン | 体細胞から多能性幹細胞を作製するための機械的操作とプログラミンの併用 |
| GB201510913D0 (en) * | 2015-06-22 | 2015-08-05 | Nat University Of Singapore And Agency For Science Technology And Res | Vascularized tissue, skin or mucosa quivalent |
| US20190093072A1 (en) | 2015-10-21 | 2019-03-28 | Indiana University Research And Technology Corporation | Methods of generating human inner ear sensory epithelia and sensory neurons |
| JP7018875B2 (ja) * | 2015-10-21 | 2022-02-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | 多能性幹細胞からのヒト皮膚オルガノイドの誘導 |
| US10273549B2 (en) | 2016-04-21 | 2019-04-30 | Vitrolabs Inc. | Engineered skin equivalent, method of manufacture thereof and products derived therefrom |
| CN110291188B (zh) * | 2016-12-09 | 2025-01-03 | 芝加哥大学 | 组织类器官 |
| CN106754652B (zh) * | 2017-03-06 | 2019-04-02 | 广州润虹医药科技股份有限公司 | iPS细胞分化成外胚层祖细胞的无血清诱导培养基及诱导方法 |
| CN106834214B (zh) * | 2017-03-27 | 2020-02-14 | 广州润虹医药科技股份有限公司 | 一种诱导多能干细胞形成角质形成细胞的诱导培养基及诱导方法 |
| JP6916318B2 (ja) * | 2017-06-30 | 2021-08-11 | ステムラボ・インコーポレイテッド | 尿細胞からケラチノサイト幹細胞への直接逆分化方法および逆分化したケラチノサイト幹細胞を利用した皮膚再生促進用組成物の製造方法 |
| CN107988147B (zh) * | 2017-12-19 | 2021-11-09 | 江汉大学 | 基于器官芯片与诱导多能干细胞的定向分化用于3d拟表皮构建的方法 |
| CN110093306B (zh) * | 2018-01-31 | 2022-12-02 | 中山大学 | 人工毛囊及其制备方法和应用 |
| EP3875581A1 (en) | 2020-03-02 | 2021-09-08 | Centre d'Etude des Cellules Souches (CECS) | Automated method for preparing keratinocytes |
| EP3875580A1 (en) | 2020-03-02 | 2021-09-08 | Centre d'Etude des Cellules Souches (CECS) | Methods for preparing keratinocytes |
| EP3875124A1 (fr) | 2020-03-02 | 2021-09-08 | Urgo Recherche Innovation Et Developpement | Procede d'obtention d'un tissu dermo-epidermique pre-vascularise |
| CN112941015B (zh) * | 2021-03-19 | 2022-03-18 | 上海爱萨尔生物科技有限公司 | 一种基于多能干细胞分化制备角质细胞的添加剂及方法 |
| CN113046300B (zh) * | 2021-03-19 | 2024-08-06 | 上海爱萨尔生物科技有限公司 | 一种基于多能干细胞分化制备角质细胞的培养方法 |
| CN112980775B (zh) * | 2021-03-19 | 2024-01-23 | 上海爱萨尔生物科技有限公司 | 一种基于多能干细胞分化制备角质细胞的培养液 |
| JP7315184B2 (ja) | 2022-02-16 | 2023-07-26 | 株式会社コーセー | 多能性幹細胞から表皮角化細胞への分化誘導方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2825370A1 (fr) * | 2001-05-31 | 2002-12-06 | Inst Nat Sante Rech Med | Keratinocytes obtenus a partir de cellules souches embryonnaires de mammiferes |
-
2009
- 2009-06-23 CN CN2009801256559A patent/CN102186969A/zh active Pending
- 2009-06-23 AU AU2009264336A patent/AU2009264336A1/en not_active Abandoned
- 2009-06-23 US US12/999,129 patent/US20110165130A1/en not_active Abandoned
- 2009-06-23 JP JP2011515354A patent/JP2011525370A/ja active Pending
- 2009-06-23 KR KR1020117001947A patent/KR20110022713A/ko not_active Withdrawn
- 2009-06-23 WO PCT/EP2009/057817 patent/WO2009156398A1/en not_active Ceased
- 2009-06-23 EP EP09769247A patent/EP2297299A1/en not_active Withdrawn
- 2009-06-23 BR BRPI0914422A patent/BRPI0914422A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0914422A2 (pt) | 2017-03-21 |
| CN102186969A (zh) | 2011-09-14 |
| US20110165130A1 (en) | 2011-07-07 |
| KR20110022713A (ko) | 2011-03-07 |
| WO2009156398A1 (en) | 2009-12-30 |
| EP2297299A1 (en) | 2011-03-23 |
| JP2011525370A (ja) | 2011-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110165130A1 (en) | Methods for Preparing Human Skin Substitutes from Human Pluripotent Stem Cells | |
| JP2011525370A5 (enExample) | ||
| EP3047019B1 (en) | A method to direct differentiation of pluripotent stem cells into functional heart muscle | |
| EP2447357B1 (en) | Methods for producing hair microfollicles and de novo papillae and their use for in vitro tests and in vivo implantations | |
| US20140106432A1 (en) | Cell mass capable of serving as a primitive organ-like structure comprised of a plurality of cell types of somatic origin | |
| WO2011104200A1 (en) | Methods for preparing human melanocytes from human pluripotent stem cells | |
| AU2003282244B2 (en) | Cultivation of hair inductive cells | |
| CN106661547B (zh) | 调控毛发生长的方法和组合物 | |
| Yoo et al. | Application of mesenchymal stem cells derived from bone marrow and umbilical cord in human hair multiplication | |
| US10398735B2 (en) | Compositions and methods for producing reconstituted skin | |
| JP2016516394A (ja) | ヒト線維芽細胞において特徴的な幹細胞であるＭｕｓｅ細胞から容易に分化した機能性メラノサイトの使用 | |
| Yonetani et al. | In vitro expansion of immature melanoblasts and their ability to repopulate melanocyte stem cells in the hair follicle | |
| US20220002678A1 (en) | Composition for reconstituting human skin tissue having hair follicles, human skin tissue model animal, and production method thereof | |
| Dong et al. | Enrichment of epidermal stem cells by rapid adherence and analysis of the reciprocal interaction of epidermal stem cells with neighboring cells using an organotypic system | |
| US20230081733A1 (en) | Methods for preparing keratinocytes | |
| CN103764816A (zh) | 重建头皮模型和筛选活性分子的方法 | |
| A Rahman | The development of in vitro models of human salivary glands | |
| HK40080429A (en) | Methods and compositions to modulate hair growth | |
| Dezawa et al. | Regenerating Melanocytes: Current Stem Cell Approaches with Focus on Muse Cells | |
| Shamis | hESC-and iPSC-Derived Fibroblasts for Skin Engineering and Repair |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |